Beijing Tongrentang Co., Ltd (600085.SS)
- Previous Close
40.83 - Open
41.20 - Bid 42.89 x --
- Ask 42.90 x --
- Day's Range
41.06 - 42.99 - 52 Week Range
39.71 - 64.28 - Volume
25,661,461 - Avg. Volume
11,926,790 - Market Cap (intraday)
58.836B - Beta (5Y Monthly) 0.27
- PE Ratio (TTM)
35.16 - EPS (TTM)
1.22 - Earnings Date --
- Forward Dividend & Yield 0.32 (0.75%)
- Ex-Dividend Date Jul 24, 2023
- 1y Target Est
54.70
Beijing Tongrentang Co., Ltd engages in the scientific research, production, distribution, and sale of Chinese medicines in China and internationally. The company provides product formulations, such as pills, powders, liquors, capsules, oral liquids, and dripping pills in the areas of cardiovascular, gynecology, heat clearing class, respiratory system, tonic and soothe the nerves, digestive system, pediatrics, expelling wind and dampness, orthopedics, five senses, skin surgery, spiritual, and food alcohol diseases. It sells its products under the brand names of Angong Niuhuang series, Tongren Niuhuang Qingxin series, Tongren Dahuoluo series, Yufeng Ningxin dripping pills, Piantan Fuxing pills, etc. The company was founded in 1997 and is headquartered in Beijing, China. Beijing Tongrentang Co., Ltd is a subsidiary of China Beijing Tongrentang (Group) Co., Ltd.
gf.tongrentang.com16,777
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: 600085.SS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 600085.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 600085.SS
Valuation Measures
Market Cap
58.84B
Enterprise Value
49.82B
Trailing P/E
35.25
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.29
Price/Book (mrq)
4.51
Enterprise Value/Revenue
2.79
Enterprise Value/EBITDA
12.16
Financial Highlights
Profitability and Income Statement
Profit Margin
9.34%
Return on Assets (ttm)
6.45%
Return on Equity (ttm)
13.34%
Revenue (ttm)
17.86B
Net Income Avi to Common (ttm)
1.67B
Diluted EPS (ttm)
1.22
Balance Sheet and Cash Flow
Total Cash (mrq)
12.13B
Total Debt/Equity (mrq)
15.80%
Levered Free Cash Flow (ttm)
1.14B
Research Analysis: 600085.SS
Company Insights: 600085.SS
600085.SS does not have Company Insights